These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 4919191)

  • 1. Current status of development of artificial organs.
    Nosé Y
    Stud Gen (Berl); 1970; 23(4):409-27. PubMed ID: 4919191
    [No Abstract]   [Full Text] [Related]  

  • 2. The Federal involvement in the care of patients with end-stage renal disease: the relationship to the nation's health properties.
    Dirks HM
    Transplant Proc; 1973 Jun; 5(2):1047-50. PubMed ID: 4579037
    [No Abstract]   [Full Text] [Related]  

  • 3. Better care aim of dialysis network.
    Cohodes A
    Hospitals; 1975 Feb; 49(4):44-8. PubMed ID: 1089592
    [No Abstract]   [Full Text] [Related]  

  • 4. The federal governments's role in management of end-stage renal disease.
    Burton BT
    Kidney Int Suppl; 1978 Jun; (8):S61-4. PubMed ID: 357816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-stage renal disease: better treatment at lower cost.
    Burton BT
    Ann Intern Med; 1978 Apr; 88(4):567-8. PubMed ID: 345908
    [No Abstract]   [Full Text] [Related]  

  • 6. The dollar benefits of biomedical research: a cost analysis.
    Fudenberg HH
    J Lab Clin Med; 1972 Mar; 79(3):353-63. PubMed ID: 4551447
    [No Abstract]   [Full Text] [Related]  

  • 7. The political history of the artificial heart.
    Strauss MJ
    N Engl J Med; 1984 Feb; 310(5):332-6. PubMed ID: 6361569
    [No Abstract]   [Full Text] [Related]  

  • 8. National priorities in the artificial kidney program.
    Burton BT
    Biomater Med Devices Artif Organs; 1974; 2(4):311-9. PubMed ID: 4618486
    [No Abstract]   [Full Text] [Related]  

  • 9. Problems of planning.
    Walsh JW
    N Engl J Med; 1969 Jun; 280(25):1422-3. PubMed ID: 4890481
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive care nursing for renal patients.
    Morgan DM
    Can Hosp; 1971 Oct; 48(10):18-20 passim. PubMed ID: 4950088
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting treatment costs and life expectancy for end-stage renal disease.
    Stange PV; Sumner AT
    N Engl J Med; 1978 Feb; 298(7):372-8. PubMed ID: 340947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic dialysis, U.S.A.--past, presnet and future.
    Burton BT
    Clin Nephrol; 1975 Jan; 3(1):3-5. PubMed ID: 805013
    [No Abstract]   [Full Text] [Related]  

  • 13. Artificial kidneys and artificial hearts.
    Rettig RA
    South Calif Law Rev; 1991 Nov; 65(1):503-28. PubMed ID: 11645844
    [No Abstract]   [Full Text] [Related]  

  • 14. The politics of transplantation.
    Iglehart JK
    N Engl J Med; 1984 Mar; 310(13):864-8. PubMed ID: 6366555
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicinal chemistry: GAO chides NIH.
    Walsh J
    Science; 1968 Aug; 161(3843):769. PubMed ID: 5663802
    [No Abstract]   [Full Text] [Related]  

  • 16. Consensus conference on indirect costs.
    FASEB J; 1991 Sep; 5(12):2624-37. PubMed ID: 1916086
    [No Abstract]   [Full Text] [Related]  

  • 17. Whither dialysis and renal transplantation?
    Burton BT
    JAMA; 1974 Dec; 230(10):1403-4. PubMed ID: 4610195
    [No Abstract]   [Full Text] [Related]  

  • 18. Secrets of the artificial heart business.
    Anderson I
    New Sci; 1984 Dec; 104(1433):7. PubMed ID: 11655657
    [No Abstract]   [Full Text] [Related]  

  • 19. A policy for biomedical research. Report of an Ad Hoc Committee of the Council of Academic Societies of the Association of American Medical Colleges.
    J Med Educ; 1971 Aug; 46(8):689-743. PubMed ID: 4997950
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of cost-benefit analysis to health systems technology.
    Klarman HE
    J Occup Med; 1974 Mar; 16(3):172-86. PubMed ID: 4593983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.